WO2007143701A3 - Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes - Google Patents

Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes Download PDF

Info

Publication number
WO2007143701A3
WO2007143701A3 PCT/US2007/070541 US2007070541W WO2007143701A3 WO 2007143701 A3 WO2007143701 A3 WO 2007143701A3 US 2007070541 W US2007070541 W US 2007070541W WO 2007143701 A3 WO2007143701 A3 WO 2007143701A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
monoclonal antibodies
methods
susceptible cells
genotypes
Prior art date
Application number
PCT/US2007/070541
Other languages
French (fr)
Other versions
WO2007143701A8 (en
WO2007143701A2 (en
Inventor
Kirsten A Nagashima
William C Olson
Paul J Maddon
Raju Koduri
Gerald P Donovan
Naoya Tsurushita
J Tso
Shankar Kumar
Original Assignee
Progenics Pharm Inc
Kirsten A Nagashima
William C Olson
Paul J Maddon
Raju Koduri
Gerald P Donovan
Naoya Tsurushita
J Tso
Shankar Kumar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, Kirsten A Nagashima, William C Olson, Paul J Maddon, Raju Koduri, Gerald P Donovan, Naoya Tsurushita, J Tso, Shankar Kumar filed Critical Progenics Pharm Inc
Publication of WO2007143701A2 publication Critical patent/WO2007143701A2/en
Publication of WO2007143701A3 publication Critical patent/WO2007143701A3/en
Publication of WO2007143701A8 publication Critical patent/WO2007143701A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

This invention provides potent HCV neutralizing monoclonal antibodies and portions thereof that inhibit entry of HCV into susceptible cells. The neutralizing monoclonal antibodies of the invention are broadly reactive against HCV of different genotypes, including genotypes 1 and 2. A particular monoclonal antibody, designated PA-29, does not bind soluble or independently-expressed HCV E1 and E2 envelope glycoproteins. A hybridoma cell line producing the PA-29 monoclonal antibody has been deposited under ATCC Accession No. PTA-7632. The described monoclonal antibodies, including PA-29 and humanized and chimeric forms thereof, serve as HCV antagonists for use in therapeutic and prophylactic methods of treating and preventing HIV infection of susceptible cells, in methods of blocking HCV entry into susceptible cells and in methods of diagnosis and detection of HCV in a sample of a subject and within a subject.
PCT/US2007/070541 2006-06-06 2007-06-06 Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes WO2007143701A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81135206P 2006-06-06 2006-06-06
US60/811,352 2006-06-06

Publications (3)

Publication Number Publication Date
WO2007143701A2 WO2007143701A2 (en) 2007-12-13
WO2007143701A3 true WO2007143701A3 (en) 2008-09-18
WO2007143701A8 WO2007143701A8 (en) 2009-07-23

Family

ID=38802325

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/070541 WO2007143701A2 (en) 2006-06-06 2007-06-06 Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes

Country Status (1)

Country Link
WO (1) WO2007143701A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694397A1 (en) * 2007-07-25 2009-01-29 Japan As Represented By Director-General Of National Institute Of Infect Ious Diseases Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
WO2010047830A2 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
CN103534351A (en) * 2011-03-31 2014-01-22 日本国立感染症研究所 Nucleic acid construct containing nucleic acid derived from genotype 1b HCV genome, HCV genome-replicating cells transfected with same, and method for producing infectious HCV particles
EP3121273A4 (en) * 2014-03-20 2017-08-30 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having infection-inhibiting activity against hepatitis c virus
WO2016130122A1 (en) * 2015-02-11 2016-08-18 Biotest Pharmaceuticals Corporation Prevention of hepatitis c virus recurrence using a human hepatits c immunoglobulin preparation
CN105254756B (en) * 2015-11-27 2018-09-07 武汉大学 A kind of monoclonal antibody and application for hepatitis C virus envelope protein E 2
CN114921418B (en) * 2022-06-23 2023-08-18 金河佑本生物制品有限公司 Hybridoma cell strain 1D3 of O-type foot-and-mouth disease virus particle monoclonal antibody, kit and detection method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CATANESE ET AL.: "High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein", JOURNAL OF VIROLOGY, vol. 81, no. 15, August 2007 (2007-08-01), pages 8063 - 8071, XP002629861, DOI: doi:10.1128/JVI.00193-07 *
COCQUEREL ET AL.: "Recognition of Native Hepatitis C Virus E1E2 Heterodimers by a Human Monoclonal Antibody", JOURNAL OF VIROLOGY, vol. 77, no. 2, January 2003 (2003-01-01), pages 1604 - 1609, XP002256295 *
GOFFARD ET AL.: "Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins", JOURNAL OF VIROLOGY, vol. 79, no. 13, July 2005 (2005-07-01), pages 8400 - 8409 *

Also Published As

Publication number Publication date
WO2007143701A8 (en) 2009-07-23
WO2007143701A2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
WO2007143701A8 (en) Monoclonal antibodies that potently neutralize hepatitis c virus (hcv) of diverse genotypes
NO20074867L (en) Antibodies to CCR5 and uses thereof
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
RU2017132160A (en) ANTIBODIES TO PD-L1 AND THEIR APPLICATION FOR STRENGTHENING T-CELL FUNCTIONS
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
NZ615012A (en) Combinatorial therapy involving alpha5beta1 antagonists
NZ568403A (en) CD20-specific antibodies and methods of employing same
RU2014143785A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF LIVER CANCER
CN102015767A (en) Cross-neutralizing human monoclonal antibodies to SARS-CoV and methods of use thereof
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ596042A (en) Humanized anti-factor d antibodies
RU2015126533A (en) ANTI-CD47 ANTIBODIES AND WAYS OF THEIR APPLICATION
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
CA2492671A1 (en) Humanized antibody and process for preparing same
JP2014111644A5 (en)
NZ616992A (en) Anti-ilt7 antibody
EP2426146A3 (en) Anti-human IL-21 monoclonal antibodies
WO2004018649A3 (en) Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2007014114A3 (en) Methods for reducing viral load in hiv-1-infected patients
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ597611A (en) Anti notch-1 antibodies
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv
EA032189B9 (en) Isolated human monoclonal antibodies against tissue factor pathway inhibitor (tfpi) and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784344

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07784344

Country of ref document: EP

Kind code of ref document: A2